clinical trial · NCT05930561
4D-150 in Patients With Diabetic Macular Edema
Diabetic Macular EdemaDiabetic Retinopathy4D-150 IVTAflibercept IVT
brief summary
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
started
Aug 9, 2023
primary completion
Feb 28, 2029
completion
Feb 28, 2029
last updated
Sep 22, 2025
detailed description
This Phase 2 trial is a prospective, multicenter, randomized, active-controlled, double-masked dose-ranging trial to evaluate the safety and efficacy of 4D-150 in adults with DME. The trial will be conducted in two parts: Dose Confirmation and Dose Expansion.
official title
A Phase 2 Randomized, Active-Controlled, Double-masked Trial of Intravitreal 4D-150 Gene Therapy in Adults With Diabetic Macular Edema (SPECTRA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol